Trial Profile

A basket trial assessing 89Zr crefmirlimab berdoxam with LEU011 in solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crefmirlimab (Primary) ; LEU-011 (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

18 Apr 2023 New trial record
12 Apr 2023 According to ImaginAb Inc., media release, ImaginAb Inc., announces the execution of a new non-exclusive License and Supply Agreement with Leucid Bio (Leucid),Under the terms of the agreement, ImaginAb will license and supply clinical doses of ImaginAb's investigational CD8 ImmunoPET tracer, 89Zr crefmirlimab berdoxam, to Leucid for use in its basket study in solid tumors, with LEU011.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com